What is Vetigenics?
Founded in 2017, Vetigenics operates at the intersection of biotechnology and veterinary medicine. The company utilizes a sophisticated phage display platform to engineer fully canine antibodies, branded as CANIBODIES. These biological building blocks are essential for the creation of monoclonal and bispecific antibodies, as well as advanced CAR T-cell therapies. By focusing on comparative oncology, the firm addresses critical health challenges in pets while simultaneously generating data that informs human therapeutic development. This dual-market strategy positions Vetigenics as a high-value player in the personalized healthcare sector, offering a scalable solution for complex disease management in both veterinary and human clinical settings.
How much funding has Vetigenics raised?
Vetigenics has raised a total of $6M across 1 funding round:
Angel/Seed
$6M
Angel/Seed (2025): $6M, investors not publicly disclosed
Key Investors in Vetigenics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Vetigenics?
Looking ahead, the strategic deployment of the $6M will likely focus on expanding the company's pipeline of therapeutic candidates and enhancing its phage display capabilities. As the firm moves deeper into the commercialization phase, the focus will shift toward establishing strategic partnerships with larger pharmaceutical entities and veterinary healthcare providers. The company is poised to leverage its unique intellectual property to address unmet needs in oncology, potentially setting new standards for cross-species medical innovation. By maintaining its commitment to rigorous scientific validation, Vetigenics is expected to drive significant long-term value for stakeholders while advancing the frontier of personalized medicine.
See full Vetigenics company page
